Long-half-life (89)Z-labeled radiotracers can guide percutaneous biopsy within the PET/CT suite without reinjection of radiotracer Journal Article


Authors: Cornelis, F. H.; Durack, J. C.; Pandit-Taskar, N.; Ulaner, G. A.; Lewis, J. S.; Morris, M. J.; Solomon, S. B.
Article Title: Long-half-life (89)Z-labeled radiotracers can guide percutaneous biopsy within the PET/CT suite without reinjection of radiotracer
Abstract: The rationale for this study was to evaluate the feasibility of withinsuite 89Zr-labeled radiotracer PET/CT-guided biopsy performed without reinjection. Methods: From 2013 to 2016, 12 patients (7 men, 5 women; mean age, 61 y; range, 40-75 y) with metastatic prostate or breast carcinoma suspected either on imaging or because of biochemical progression underwent 14 percutaneous biopsies after diagnostic PET/CT using 89Zr-labeled radiotracers (mean dose, 180 MBq; range, 126-189 MBq) targeting prostatespecific membrane antigen (n 5 7) or human epidermal growth factor receptor 2 (n 5 5). Biopsy was performed within a PET/CT suite without radiotracer reinjection. Results: There were no complications in any biopsies, which were performed a mean of 6.2 d (range, 0-13 d) after injection of the radiotracer. The biopsy sites were bone (n 5 7), pleura (n 5 3), lymph nodes (n 5 2), and liver (n 5 2). On pathologic examination of the biopsy samples, all were positive for malignancy. The initial diagnostic imaging findings were concordant with the biopsy results. The additional radiation (mean dose-length product) due to the CT procedures was 1,581 mGy/cm (range, 379-2,686 mGy/cm). Conclusion: PET/CT-guided biopsy using 89Zr-labeled radiotracers is safe and effective without tracer reinjection. © 2018 by the Society of Nuclear Medicine and Molecular Imaging.
Keywords: metastasis; biopsy; interventional radiology; pet/ct; 89zr
Journal Title: Journal of Nuclear Medicine
Volume: 59
Issue: 3
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2018-03-01
Start Page: 399
End Page: 402
Language: English
DOI: 10.2967/jnumed.117.194480
PROVIDER: scopus
PMCID: PMC5868497
PUBMED: 28818992
DOI/URL:
Notes: Article -- Export Date: 1 May 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gary Ulaner
    146 Ulaner
  2. Michael Morris
    577 Morris
  3. Stephen Solomon
    422 Solomon
  4. Jason S Lewis
    456 Lewis
  5. Jeremy Charles Durack
    116 Durack